First patient dosed with Nuformix cocrystal product Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small … Continue reading “Nuformix Commences NXP001 Clinical Trial”
Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect. Dr Haurum … Continue reading “NeoPhore appoints Dr John Haurum as Non-Executive Director”
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix co-leads a $63 million Series B investment in new portfolio company Imara Arix commits … Continue reading “Arix co-leads $63 million Series B investment round for Imara”
Michael Lahn appointed Chief Medical Officer Zoë Johnson appointed Chief Scientific Officer Geneva, Switzerland, 12 March 2019: iOnctura SA, the late stage preclinical immuno-oncology company, announced today the completion of … Continue reading “iOnctura bolsters management team with senior appointments”
Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis Turku, Finland, March 07 2019: Forendo Pharma, a clinical stage drug development company focusing on … Continue reading “Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis”
March 6, 2019. Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the appointment of Dan Furrer as Head of … Continue reading “European CNS specialist Neuraxpharm appoints Dan Furrer as Head of Corporate Marketing”
Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019 Amsterdam, The Netherlands, March 5, 2019 – Kiadis Pharma N.V. (“Kiadis … Continue reading “Kiadis Pharma Strengthens Management Team”
Geneva, Switzerland, 28th February 2019: iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled “Preclinical development of a novel, highly selective PI3Kδ … Continue reading “iOnctura selected for an oral presentation at 2019 AACR Annual Meeting”
Cambridge, UK – 27th February 2019 Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has received approval from … Continue reading “Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies”
LOS ANGELES, Feb. 26, 2019 – ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately. … Continue reading “ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board”
LONDON, 19 February 2019: Arix Bioscience plc (LSE:ARIX) (“Arix” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, … Continue reading “Arix Bioscience announces Management and Board changes Joe Anderson appointed as CEO”
Funding rises for early assets MedNous Feb 2019 Published in the February 2019 edition of MedNous, a publication of Evernow Publishing Ltd … Continue reading “Meeting Report: Funding rises for early assets”
European CNS specialist Neuraxpharm strengthens French business Dr. Pierre-Hervé Brun appointed new General Manager of Neuraxpharm France Paris, February 14th, 2019. Neuraxpharm France, the French affiliate of Neuraxpharm Group, a … Continue reading “European CNS specialist Neuraxpharm strengthens French business”
Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that it will host its first … Continue reading “Futura Medical to hold its First European Advisory Panel Meeting at the European Society of Sexual Medicine (ESSM)”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Primary biliary … Continue reading “Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis”
Cambridge, UK, 11 February 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of … Continue reading “Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director”
Guildford, UK – 06 February 2019: HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces today that it will present a poster … Continue reading “HOX THERAPEUTICS TO PRESENT AT 2019 AACR ANNUAL MEETING”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis … Continue reading “Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis”
Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer Amsterdam, The Netherlands, and Boston, Massachusetts, USA – February 4, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext … Continue reading “Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com